SK bioscience and Sanofi have expanded their agreement to jointly develop pneumococcal conjugate vaccines (PCVs) targeting ...

The pneumococcal conjugate vaccine – codenamed PCV21/GBP410 – has started pivotal trials in the prevention of both paediatric ...

Sanofi SNY and its partner SK bioscience announced that they have expanded their agreement to develop, license and ...

Sanofi is handing SK bioscience 50 million euros ($52 million) as the longtime partners take their next-gen pneumococcal ...

SK Bioscience, Sanofi collaborate on next-gen pneumococcal vaccine development SK Bioscience and Sanofi join forces to ...

SK Bioscience and global pharmaceutical giant Sanofi signed an expanded agreement to jointly develop next-generation ...

French pharma major Sanofi says it has entered into a new chapter of the collaboration with South Korean firm SK bioscience ...

South Korean pharmaceutical company SK Bioscience said Monday that it has joined forces with French drugmaker Sanofi to ...

In this cluster-randomized controlled trial, it was found that a pneumococcal conjugate vaccine (PCV) schedule involving a ...

The following is a summary of “Evaluating Sex Differences in Pneumococcal Disease Burden and Vaccination Effectiveness in ...

Goldman Sachs rates Vaxcyte a buy with $135 price target, highlighting vaccine platform and pneumonia candidate. Read more ...

Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines Pneumococcal disease remains a major global health challenge ...